Irhythm Technologies Inc Stock Price, News & Analysis

iRhythm Technologies (IRTC) presented new data at ADA 2025 revealing significant findings about cardiac arrhythmias in type 2 diabetes (T2D) and chronic kidney disease (CKD) patients. The study analyzed over 30 million U.S. adults, showing that of 8.8 million T2D patients, 1.1 million developed major arrhythmias, with 47% occurring post-diabetes diagnosis. In the T2D+CKD population of 3.2 million patients, 21% developed major arrhythmias, with 59% occurring before CKD diagnosis. The research highlighted that arrhythmias often precede major cardiovascular events (MACE), with 17% of patients experiencing MACE within three days of arrhythmia. The findings suggest that early detection of arrhythmias could be crucial for preventing complications, especially since previous data showed that fewer than one in five patients experience symptoms during arrhythmic episodes.

iRhythm Technologies (NASDAQ:IRTC), a digital health care company specializing in disease detection, prevention, and prediction solutions, has announced its management team's participation in three upcoming investor conferences in June 2025:

• William Blair 45th Annual Growth Stock Conference on June 4, 2025, at 2:00 PM CT
• Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, at 2:40 PM ET
• Truist Securities MedTech Conference on June 17, 2025, at 1:40 PM ET

Live and archived webcasts will be available on the company's investor website at investors.irhythmtech.com.

iRhythm Technologies (NASDAQ:IRTC) has launched its Zio® ECG Recording and Analysis System in Japan, marking its entry into the world's second-largest ambulatory cardiac monitoring market. The system offers up to 14 days of continuous ECG monitoring, powered by PMDA-approved AI algorithms capable of detecting 13 arrhythmia types. The Zio monitor features a lightweight, comfortable patch design with 99% patient compliance and analyzable data rates. The system combines AI technology with human expertise through certified cardiographic technician review, achieving 99% physician agreement. Japan's market, with approximately 1.6 million tests prescribed annually, represents a significant opportunity as the country faces increasing arrhythmia prevalence in its aging population. The nationwide rollout is expected to complete by July 2025, distributed exclusively through Senko Medical Instrument.

iRhythm Technologies (NASDAQ: IRTC) reported strong Q1 2025 financial results with revenue of $158.7 million, up 20.3% year-over-year. The company achieved a gross margin of 68.8%, representing a 250-basis point increase from Q1 2024. Despite revenue growth, iRhythm posted a net loss of $30.7 million, though improved from $45.7 million loss in Q1 2024. Key operational highlights include expansion into Japan, strong Zio AT demand in the US and UK, and positive clinical study results showing superior arrhythmia detection rates. The company maintains a strong financial position with $520.6 million in cash and marketable securities. For full-year 2025, iRhythm raised guidance, projecting revenue between $690-700 million and adjusted EBITDA margin of 7.5-8.5%.

iRhythm Technologies, a digital health care company specializing in disease detection, prevention, and prediction solutions, has announced its participation in the upcoming Bank of America Securities 2025 Health Care Conference.

The company's management team is set to deliver their presentation on Tuesday, May 13, 2025, at 3:40 p.m. Pacific Time (6:40 p.m. Eastern Time). Investors and interested parties can access both the live presentation and its archived version through the "Events & Presentations" section on iRhythm's investor website at investors.irhythmtech.com.

iRhythm Technologies (NASDAQ:IRTC) presented new real-world data from the AVALON study at HRS2025, demonstrating the clinical superiority of their Zio long-term continuous monitoring (LTCM) service. The study analyzed 428,707 commercially insured patients, showing Zio LTCM achieved:

- Highest diagnostic yield (26.5%) compared to other monitoring services
- 2.04x higher likelihood of arrhythmia diagnosis vs. Holter monitors
- Lowest likelihood of repeat testing within 180 days
- Reduced cardiovascular events risk within 1 year

The Zio LTCM service includes a patch-based ECG monitor capturing 14 days of continuous data and the ZEUS system with FDA-cleared AI algorithm. The study expands on previous CAMELOT findings in Medicare patients, now confirming benefits in younger, commercially insured populations (mean age: 46 years).

iRhythm Technologies (NASDAQ:IRTC), a digital health care company specializing in disease detection, prevention, and prediction solutions, has scheduled its first quarter 2025 financial results announcement for May 1, 2025, after market close.

The company will host a conference call with management at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Investors can access both live and archived versions of the conference call through the 'Quarterly Results' section on iRhythm's investor website at investors.irhythmtech.com.

iRhythm Technologies (NASDAQ:IRTC) has released its 2024 Corporate Sustainability Report, showcasing the company's progress in building a sustainable and inclusive future. The report focuses on four key pillars:

• Quality and Sustainable Technology Innovation: Enhanced quality systems, improved EHR integration, secured strategic licensing, and formed an AI Governance Committee
• Access and Health Equity: Expanded to four European countries and received Japanese regulatory approval for Zio® 14-day ECG monitoring system
• Workforce and Inclusion: Refreshed core values, revised code of conduct, and introduced new employee recognition programs
• Environmental Impact: Completed Scope 3 emissions inventory, achieved 89.5% landfill waste diversion, obtained ISO 14001:2015 certification, and was named to Newsweek's America's Greenest Companies 2025

Turing Medical has appointed Kevin King, former CEO of iRhythm Technologies, as its new President and Chief Executive Officer. King brings over 30 years of experience in healthcare and technology, having previously led companies like Affymetrix and Thomson Reuters Healthcare.

The company, focused on precision brain mapping and targeting technologies, is developing advanced functional connectivity MRI processing techniques. Under King's leadership, Turing Medical plans to launch a clinical trial of its PACE Therapy for Treatment Resistant Depression, integrating their Bullsai platform with minimally invasive neuromodulation therapy.

Recent company achievements include FDA 510(k) clearance for the Bullsai platform, an automated cloud-based system for neurosurgical planning, and successful marketing of FIRMM and FIRMM-pix MRI motion monitoring software solutions since 2022.